Alzheimer's Drug Diversity
The FDA's recent approval of lecanumab has sparked excitement due to its ability to slow cognitive decline in Alzheimer's patients. However, questions arise about the trial's representation of diverse populations, particularly for Black and Latino patients who are at higher risk for the disease. Despite being the most racially diverse Alzheimer's trial to date, the data may not provide sufficient insights into how these groups are affected by the drug.In this clip
From this podcast
Short Wave
How Well Does A New Alzheimer's Drug Work For Those Most At Risk?
Related Questions